my take on cuv9900 is simple.
At this moment they dont have enough resources to develop cuv9900 further. Apart from that also ple and vitiligo results are behind schedule.
I think it would not help the MAA and discussions with ema if cuv anticipates this drug for wider use and global audience. EMA strategy has been clearly focused on use for limited number of indications with no other options for treatment. Totally excluding cosmetic market and dropping efforts for ple and su. Some claim that ple is almost cosmetic.
my take on cuv9900 is simple.At this moment they dont have...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.90 |
Change
0.760(5.02%) |
Mkt cap ! $796.6M | |||
| Open | High | Low | Value | Volume |
| $15.26 | $15.90 | $15.01 | $1.431M | 91.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 183 | $15.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.90 | 557 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.54 |
Change
0.760 ( 2.29 %) |
||||
| Open | High | Low | Volume | ||
| $15.26 | $15.61 | $15.26 | 3366 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| CUV (ASX) Chart |